Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
Cytosorbents Corporation develops blood purification technologies for life-threatening conditions in intensive care and cardiac surgery. Its lead product, CytoSorb®, is approved in the European Union, distributed internationally, and used for cytokine adsorption and CE-marked applications that include bilirubin, myoglobin, ticagrelor, and rivaroxaban removal; in the United States it has FDA Emergency Use Authorization for adult critically ill COVID-19 patients with respiratory failure and is not otherwise approved or cleared.
Company updates commonly address quarterly and annual results, gross margin and balance-sheet actions, product launches such as HotSwap™, distribution partnerships, clinical evidence for CytoSorb therapy, and regulatory work around the investigational DrugSorb®-ATR antithrombotic removal system. The product portfolio also includes ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, ContrastSorb, PuriFi®, and related blood purification technologies.
CytoSorbents (NASDAQ: CTSO) has launched the PuriFi™ blood pump in the European Union following approval under the E.U. Medical Device Regulation (MDR). This peristaltic blood pump features innovative elements such as pre-assembled blood line kits, auto-priming, an auto-leveling bubble catcher, an intuitive touchscreen interface, optional blood warming, and a rapid 10-minute set-up time. These advancements facilitate the use of CytoSorbents’ CytoSorb® blood purification cartridge for critically ill and cardiac surgery patients. The launch, a result of a 2-year development program with Medica Group, aims to meet growing demand for efficient blood purification solutions.
CytoSorbents (NASDAQ: CTSO), a key player in blood purification for critical care and cardiac surgery, will hold its 2024 Virtual Annual Stockholders Meeting on June 6, 2024, at 10 AM EDT. Stockholders as of April 12, 2024, are entitled to participate using the 16-digit control number provided in their proxy materials. The webcast will be accessible at www.virtualshareholdermeeting.com/CTSO2024.
CytoSorbents (NASDAQ: CTSO) presented new data from the STAR Registry at the EuroPCR 2024 conference. The study, involving 102 patients on ticagrelor undergoing CABG surgery with CytoSorb blood purification, showed no device-related adverse events and a 9.8% rate of severe bleeding. The data suggest CytoSorb may reduce the wait time for surgery, lowering bleeding risks compared to historical data. This research was a top five finalist for the best scientific abstract. The results could expand CytoSorb's market as ticagrelor's patent expires and generic options become available.
CytoSorbents reported unaudited financial results for the first quarter of 2024, showcasing a robust 14% increase in product sales year over year and a 22% sequential increase. The company's product gross margins improved to 76%, marking the highest quarter for core CytoSorb sales in nearly 3 years. Additionally, the STAR-T data presented at AATS supported a favorable benefit-to-risk profile of DrugSorb-ATR in CABG patients. CytoSorbents is on track for FDA De Novo and Health Canada submissions for DrugSorb-ATR in Q3 2024.
CytoSorbents announced a virtual Key Opinion Leader and Analyst-Investor Day to discuss the STAR-T pivotal trial results and real-world experience with antithrombotic drug removal in Europe. The event will focus on severe perioperative bleeding in heart surgery patients on blood thinners, including Brilinta®. Experts will present key findings from the STAR-T trial and real-world data in the pre-specified CABG population, addressing the challenges of coronary artery disease and heart attacks globally.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.